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Since the widespread introduction of peritoneal dialysis (PD)
into the standard care of patients with chronic kidney disease
there has been a shift from the initial focus on technique
survival to refinement of the therapy to enhance
biocompatibility and improve both the local peritoneal and
systemic consequences of PD. One of the most significant
contributions to these advances has been the development
of novel PD solutions. The use of new manufacturing
techniques, buffer presentation, and new osmotic
alternatives to glucose have allowed potentially improved
peritoneal survival (in terms of structure and function) and
improved subjective patient experience. Additional benefits
have also included, enhanced management of salt and water
removal, supported nutritional status and improvement in
the systemic metabolic derangements associated with
conventional PD treatment, based on glucose-containing
lactate-buffered solutions. The selection of suitable targets
for modulation of therapy continues to be hampered by our
continued relative ignorance of the local and particularly
systemic effects of PD compounded by the dearth of quality,
outcome-based studies. The aim of this review is to
summarize the characteristics of the next generation of PD
fluids currently available, and then to evaluate their possible
place in treatment by considering the difference in their
effects in a series of structural and functional areas
potentially relevant to improving patient outcomes.
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NEW PD SOLUTIONS
The choices made in the design of conventional peritoneal
dialysis (PD) fluids were based on attempting to mimic
normal plasma, tempered by a series of compromises to allow
production, and ultimate stability under storage conditions
of the fluids. These imperatives resulted in glucose being used
as the main osmotic agent, buffered with lactate alone (to
produce a low pH). This allowed sterilization of the fluids by
heat and avoid caramalization of the glucose. The use of
glucose in PD fluid (and in particular the higher concentra-
tions required to provide enhanced ultrafiltration) has direct
deleterious effects on peritoneal structure (diabetiform
change)1,2 and function. Low pH results in increased infusion
pain3 and directly effects neoangiogenesis and mesothelial
cell damage.4 In combination with the commercial manu-
facturing process these factors also result in the production of
glucose degradation products (GDPs).5 These possess well-
defined local toxicities to the peritoneal membrane and are
also systemically absorbed (with a range of currently
inadequately defined biological effects). GDPs also enhance
the local and systemic production of advanced glycation end
products by the reaction of the aldehyde form of glucose, in
the presence of amines or proteins, to produce Amadori
glycosolation products.6 Advanced glycation end product
accumulation has been implicated in the development of
structural damage of the peritoneum and vasculature.7
The newer generations of PD solutions have sought to
utilize more physiological intraperitoneal pH, and reduce
GDP production by a combination of this reduced pH with
improved manufacturing and product presentation. The
choice of glucose alternatives further reduces the potential to
generate GDPs. Enhanced biocompatibility is achieved to
varying degrees depending on the approaches used.
The avoidance of hypertonic glucose itself has emerged as
a therapeutic aim for both local peritoneal and systemic
exposure reasons. The use of alternatives that are absorbed
(amino acids) has also been developed to enhance nutrition
in depleted patients.
There are two main groups of products currently
commercially available. Multibag systems separate out the
buffer (either lactate or bicarbonate/lactate mix). This allows
the glucose to be stored at a low pH and minimizes
degradation during protracted storage.8 It also prevents the
precipitation that would result in the mixing of a bicarbonate
buffer and magnesium and calcium in solution. Both Baxter
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and Fresenius produce two bag systems resulting in a more
physiological intraperitoneal pH. Physioneals fluids from
Baxter utilize a lactate/bicarbonate mixed buffer (ph 7–7.4).
The use of bicarbonate/lactate mix (25 mmol/l bicarbonate
with 15 mmol/l lactate) was favored over pure bicarbonate
buffering owing to lower infusion pain scoring.3 The
Fresenius Stay Safe Balances system separates glucose and
electrolytes from a lactate buffer and results in a neutral pH
once mixed. The bicaVeras system utilizes a pure bicarbo-
nate buffer (34 mmol/l), which although does not result in a
more physiological pH, does avoid potentially deleterious
local effects attributable to lactate. Gambro produce Gam-
brosol Trios (a lactate-buffered three bag system) which also
separates the hypertonic glucose component, allowing a
solution of differing tonicity to be mixed before use,
depending on the ultimate combination of compartments
performed. Although lactate buffered this still results in a
higher pH than characteristically seen with earlier generation
low biocompatibility solutions (pH 6.5 c.f. 5.5). There are
currently no quality data comparing these newer generation
of lower GDP-containing glucose-based solutions against
each other in clinical practice.
The second group consist of alternatives to glucose as an
osmotic agent. Baxter market Extraneals (7.5% icodextrin).
This contains a glucose polymer that is only absorbed after
having undergone a degree intraperitoneal hydrolysis
(ultimately to maltose). Currently this is buffered with
lactate alone (although a lactate/bicarbonate-buffered alter-
native is undergoing formal clinical evaluation), and has a
lower GDP content than conventional PD fluids.9 This
provides an ultrafiltration capacity broadly similar to 2.27%
glucose-containing solutions, but owing to a reduced back
diffusion from intraperitoneal cavity into the circulation
allows longer sustained ultrafiltration, particularly suited to
long dwells.10 Concerns about higher levels of circulating
maltose limit use of these solutions to a single daily exchange.
Hypersensitivity can occur.11 Baxter also produces Nutri-
neals (1.1% amino-acid-containing solution). This is
presented as a single bag lactate-buffered fluid (40 mmol/l)
and has the equivalent ultrafiltration capacity of 1.36%
glucose-containing fluids. It’s use further avoids glucose
exposure, and contains no GDPs. It has been demonstrated
to enhance nutrition in hypoalbuminemic continuous
ambulatory peritoneal dialysis patients,12 but is also limited
to single daily use owing to the potential for increased
symptomatic uremia and acidosis with increased exposure.13
POTENTIAL BENEFITS OF NEW PD SOLUTIONS
Local peritoneal effects
The majority of direct toxicity to the peritoneum appears to
be attributable to GDPs rather than pH, lactate, osmolality,
or glucose per se. A variety of GDPs are characteristically
formed but they appear to have differing toxic potential.14
Mesothelial toxicity is attributable both directly to GDPs and
as a result of local advanced glycation end product
formation.15 advanced glycation end products accumulate
in the peritoneal membrane and contribute to angiogenesis
and subsequent diabetiform change.16 Use of low GDP-
containing solution (Fresenius Balances) was associated with
improved viability and proliferation of mesothelial cells, as
evidenced by increased levels of Ca-125 and fibronectin in
peritoneal effluent, in medium comparative study against
conventional PD fluids.17 Experimental data also suggest that
lower GDP-containing solutions are associated with im-
proved mesothelial-based healing.18 Similar effects have also
been reported with other low GDP-containing glucose-based
fluids. Extraneals usage compared to higher hypertonic
glucose exposure has also been demonstrated to be associated
with improved preservation of peritoneal function.19 Nu-
trineals has been inadequately evaluated in man in this
respect, but some data exist that suggest that it has a similarly
protective effective on the peritoneum.20
Low GDP-containing solutions also appear to reduce
intraperitoneal inflammation21 and be associated with better
maintenance of macrophage function. Whether or not these
effects are associated with reduced peritonitis rates is still
awaiting robust randomized controlled trial-based study.
However data from registry sources suggests that peritonitis
rate was significantly reduced in patients receiving Physio-
neals compared to standard PD solutions.22 Use of
Physioneals is certainly associated with reduced infusion
pain3 and improved sleep when used as a part of an
automated PD regimen.23
SYSTEMIC EFFECTS
Salt and water removal
The adequate control of total body water and sodium are key
therapeutic targets for effective renal replacement therapy.
Failure to do so leads to hypertension and chronic volume
overload. These effects on left ventricular mass have been well
established as being an independent cardiovascular risk factor
in this patient group.24 The two key elements to achieving
this in PD patients are the effects of the dialysis solution itself
on sustained ultrafiltration, and any effects on the main-
tenance of residual renal function (RRF) (Tables 1 and 2).
The use of icodextrin-based fluids is associated with an
improved fluid status in prospective study.25 Extracellular
water and total body water were better controlled compared
to patients relying exclusively on the use of high glucose
concentration fluids. Icodextrin was also associated with
better maintenance of residual urine output. Earlier reports
that icodextrin use is associated with a more rapid loss of
RRF appear to be owing to the effects of inappropriate fluid
reduction in a small sub group of patients, resulting in a
clinical underhydration.26 Icodextrin use is also associated
with an increased mass transfer area coefficient and an
increased convective contribution to small solute and free
water removal.27 Low sodium dialysate, to enhance diffusive
removal, is currently under evaluation. Results are not yet
available form this therapeutic approach.
Initial study of bicarbonate/lactate-buffered PD solutions
suggested that net ultrafiltration at peritoneal equilibration
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test after 6-month follow-up was higher than with conven-
tional-buffered glucose-containing fluid usage.28 A combina-
tion of bicarbonate/lactate-buffered solutions with icodextrin
and amino-acid-containing fluids, when studied against
conventional fluids, resulted in a lesser reduction in residual
creatinine clearance, after 6 months of use. However this
effect on RRF was not seen consistently throughout all
components of the study, and some differences in RRF
between the groups did exist on inclusion. The overall effects
of fluid biocompatibility c.f. glucose exposure reduction is
not possible to determine from this study.29 The GDP, 3,4-
dideoxyglucosone-3-ene is toxic to cultured tubular cells at
biologically relevant concentrations,30 and this may be a
potential mechanism in RRF loss.
Metabolic effects and cardiovascular risk modification
Other than the modulation of overall hydration, the effects
that PD fluids are capable of having beyond the membrane
are largely determined by the absorption of the osmotic agent
(glucose or amino acids) and the systemic exposure to GDPs.
These effects result in profound metabolic, body composi-
tional, lipid, endocrine, and cardiovascular structural/
functional perturbations.
Metabolic effects
Intraperitoneal glucose exposure is associated with poorer
glycemic control in diabetic continuous ambulatory perito-
neal dialysis patients. Substitution of glucose-based conven-
tional fluids for a regimen based on bicarbonate/lactate
buffered 1.36% glucose, icodextrin and amino-acid-based
solutions resulted in improved blood glucose levels and a
reduction in hyperglycemic excursions. The use of similar
glucose exposure in a more biocompatible Physioneals
format c.f. standard solutions was also associated with a small
improvement in mean blood glucose levels.31 The mechan-
isms for this are unknown.
Intraperitoneal glucose exposure results in significant
amounts of absorption. This results in loss of the osmotic
gradient (with impaired ultrafiltration). Furthermore higher
glucose concentration use also results in hyperglycemia with
Table 1 | Summary of the characteristics of currently widely available multibag PD solutions
Manufacturer Potential drawbacks Potential benefits
Lactate buffered
Balances
Gambrosol Trios
Fresenius Gambro More physiological pH, but not neutral
Local and systemic glucose exposure
Lower GDP levels
More physiological pH
Improved peritoneal membrane biocompatibility
Preserved membrane defence
Lactate/bicarbonate buffered
Physioneals
Baxter Local and systemic glucose exposure
Does not eliminate peritoneal lactate exposure
Lower GDP levels
More physiological pH
Improved peritoneal membrane biocompatibility
Preserved membrane defence
Reduced infusion pain
Bicarbonate buffered
BicaVeras
Fresenius Local and systemic glucose exposure Lower GDP levels
More physiological pH
Improved peritoneal membrane biocompatibility
Preserved membrane defence
Improved correction of acidosis
GDP, glucose degradation product; PD, peritoneal dialysis.
Table 2 | Summary of the characteristics of currently widely available single bag PD solutions
Manufacturer Potential drawbacks Potential Benefits
Lactate-buffered glucose containing
Dianeals
Baxter Low pH
High GDP content
Poor peritoneal membrane
biocompatibility
Infusion pain
Local and systemic glucose exposure
Ease of manufacture
Low cost
Icodextrin-containing
Lactate buffered
Baxter Hypersensitivity
Low pH
Licensed for single daily use only
Lactate containing
Sustained ultrafiltration
Preservation of RRF
Hypertonic glucose replacement
Reduced hyperglycemia
Improved short term systemic
hemodynamic profile
Desirable effects on metabolic profile and
body composition
Amino-acid containing
Nutrineals
Baxter Low pH
Licensed for single daily use only (avoid
exacerbation of uremic symptoms and
acidosis)
No GDPsAvoid systemic and peritoneal
glucose exposure
Peritoneal membrane protection
Enhance nutrition
GDP, glucose degradation product; PD, peritoneal dialysis; RRF, residual renal function.
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associated hyperinsulinemia (even in non-diabetic pa-
tients).32 Hyperinsulinemia is a well-recognized additional
cardiovascular risk factor. It is also associated with systemic
cardiovascular functional changes and results in increased
stroke volume with a significant hypertensive response. These
changes seen with hypertonic glucose are not related to
alterations in cardiac filling.33 In the longer term the
increased carbohydrate load also predisposes to abnormalities
of lipid metabolism, and increased insulin resistance. The
substitution of hypertonic glucose with icodextrin appears to
be capable of ameliorating these effects.34
Body composition
Use of higher concentrations of glucose in PD regimens is
associated with an increase in drained body weight, as a result
of increased fat mass.25 Avoidance of hypertonic glucose,
with substitution by either icodextrin or amino-acid-based
PD fluids, has been reported to abrogate most of these effects.
Patients with chronic kidney disease exhibit muscle wast-
ing,35 and this is associated with poorer long-term outcomes.
PD patients exhibit greater degrees of muscle mass loss over a
12 month follow-up period than chronic kidney disease 4 or
established hemodialysis patients of similar dialysis vintage.36
Furthermore, initiation of dialysis with PD resulted in a
greater incremental decline in functionally significant muscle
mass than those commencing hemodialysis. Patients with PD
regimens with a higher exposure to glucose had proportio-
nately more muscle wasting and increased fat accumulation
than those with lower weekly glucose exposure. This may be
as a result of altered intramuscular insulin-like growth factor
signalling in the setting of hyperinsulinemia. Whether or not
this is amenable to glucose substitution awaits further
prospective study.
Amino-acid-containing PD solution usage increases
muscular amino-acid utilization37 and is related to an
increase in serum albumin, in short to medium term study
of hypoalbuminemic PD patients.38 Whether or not this is
capable of meaningfully retaining muscle mass and improv-
ing outcomes in malnourished PD patients has not been
directly studied.
Cardiovascular structure and function
The undesirable cardiovascular status of PD patients is
further worsened by a deleterious increase in serum leptin
and relative reduction in adiponectin.39 These are modulated
by visceral fat in particular, but significant changes occur
early after therapy initiation before significant changes in
body composition.40 In vitro work has suggested that high
glucose PD fluids are capable of directly modulating
adipokine release from adipocytes41 and use of glucose-free
alternatives may modulate these levels in vivo.42
Vascular calcification is increasingly appreciated as being
an important driver of cardiovascular mortality in chronic
kidney disease patients. PD is associated with a lower
calcification burden as compared with matched hemodialysis
patients.43 Indeed progression over a 1-year period was
similar to that seen in chronic kidney disease 4 patients, and
significantly less than those on hemodialysis. These changes
in peripheral vascular calcification were proportional to
changes in arterial stiffness over the corresponding period.44
Multivariate assessment of the factors associated with the
change in calcification score revealed that not only dialysis
modality was important, but also a maintained ability to
eliminate calcium. Maintenance of RRF and sustained
peritoneal removal of calcium (highly dependant on ultra-
filtration volumes) may be important.45 Use of icodextrin-
based fluids may have an advantage in this respect over
conventional choices. Serum phosphate is also a major risk
factor in the development of arterial calcification. Provision
of dietary protein with intraperitoneal amino acids (around
30% of daily requirement), without the delivered phosphate
load attendant with oral complex protein may also be
potentially significant.46
The systemic effects of absorbed GDPs are largely
unknown. They appear to have some ability to modulate
cardiovascular performance though. Our group has demon-
strated significant differences in the cardiac output changes
associated with PD exposure to 3.86% glucose dependant on
the biocompatibility of the fluid presentation. No differences
in venous bicarbonate were observed. GDP content was
therefore the only significant differences between the two
phases of study.33 The clinical significance of these observa-
tions is still to be determined.
CONCLUSION
Registry-based study does suggest survival benefit associated
with the use of low GDP biocompatible glucose-based
solutions.47 There are a plethora of peritoneal and systemic
structural, metabolic, and functional abnormalities that are
related to the use of conventional fluids. Many of these adverse
profiles can be addressed by the use of some or all of the
expanding range of PD fluids. Potentially the optimal
therapeutic approach may involve the combination of a variety
of products, to gain the maximum potential benefits of high
biocompatibility and maximum glucose substitution. The
evidence is compelling that there are clear benefits for the
patient. The major barrier to more widespread adoption of the
current generation of PD fluids is related to increased
acquisition costs. The difficult choices that health-care
providers need to make are severely hampered by the lack of
quality prospective outcome-based studies of these solutions
directly compared to conventional glucose/lactate-based pro-
ducts. The design and execution of such appropriately powered
hard outcome-based studies remains an urgent priority.
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